Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
More News related to AMLN
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
- FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
- Hapoalim Securities Upgrades Amylin (AMLN) to Hold; Two Important Milestones Achieved
More News related to NVO
- Novo Nordisk is Changing Possibilities in Hemophilia
- New Study Finds Significant Inconsistency With How Diabetes Quality of Care is Measured
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
- Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
More News related to SNY
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
- Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on Q3 '09 Earning and Outlook
Several stocks with products related to the treatment of diabetes are seeing unusual investor interest today amid reports out of Europe that an unidentified clinical study showed long-acting insulin users may have increased risks to cancer.
As Sanofi Aventis (NYSE: SNY) and Novo Nordisk (NYSE: NVO) both market such long-act insulin products (Lantus and Levemir, respectively), their stocks are falling on the news today, while shares of Amylin (Nasdaq: AMLN), which offers a non-insulin based diabetes treatment (Byetta), are rising on the news. Sanofi most recently traded at $28.60, down 5.3% from yesterday's close, Novo Nordisk is down 1% and Amylin shares are up 9.5% to $13.79.
Responding to the reports, and certainly adding downside to today's move lower, numerous analysts are out with downgrades of Sanofi Aventis. JPMorgan downgraded the stock from Overweight to Neutral, while a Morgan Stanley analyst moved the firm's investment rating on Sanofi from Overweight to Equal Weight.
Related Categories
DowngradesInsiders' Blog
Stocks Mentioned
+0.04
-0.34Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
